When psoriasis manifests in palmoplantar and intertriginous regions or on the nails, this often poses a therapeutic challenge. Several recently presented analyses on the effects of anti-IL-23p19 antibodies currently approved for psoriasis focused on patient populations with infestation of these difficult-to-treat body regions.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Hodgkin's lymphoma
No more transplants for relapsed or refractory HL in the future?
- Gram-negative foot infection
Not to be taken lightly
- Severe asthma
Anti-IL-5/-5Rα biologics impress in the real world
- Significance, diagnostics and treatment options for cardiology practice
Coronary artery spasm and atherosclerosis
- Smoldering multiple myeloma
Daratumumab delays progression in smoldering multiple myeloma
- Invitation to the 12th IBD Roadshow | June 23-25, 2025 | with Professor Bruce Sands
Acceleration in IBD Treatment: How early and holistic care leads to better outcomes
- Chronic hand eczema
Changing therapy landscape – a lot is happening
- Chronic obstructive pulmonary disease